SSDP Condemns DEA 7-OH Emergency Scheduling Order Published Over July 4 Holiday Weekend

Why it matters

A major drug-policy reform organization is pushing back against the DEA's move to temporarily classify 7-hydroxymitragynine and related substances as Schedule I, warning that the order could hamper promising pain and addiction research while pushing vulnerable people toward more dangerous drugs. The public comment window on the threshold closes July 31.

The big picture

On July 1, the DEA published two Notices of Intent to temporarily schedule 7-OH and three synthetic kratom-derived compounds. The announcements were timed during the Independence Day holiday weekend. Students for Sensible Drug Policy (SSDP), a harm-reduction advocacy organization, argues that emergency scheduling sidesteps rigorous scientific review, threatens research pipelines, and may worsen outcomes for people who use kratom to avoid harder opioids.

Key findings

• DEA published two sweeping emergency scheduling notices on July 1, 2026, targeting 7-OH and three synthetic compounds over a holiday weekend
• SSDP Executive Director Kat Murti says the order prioritizes criminalization over harm reduction and evidence-based policy
• The organization warns that Schedule I status will restrict scientific research into these compounds as potential pain or addiction treatments
• Public comments on the HHS Request for Information (docket HHS-OASH-2026-0232) are open through July 31, 2026
• SSDP is urging clinicians, researchers, and affected individuals to submit evidence-based comments before the deadline

What they say

"While much of the country was focused on the Independence Day holiday weekend, the Drug Enforcement Administration quietly published two sweeping emergency scheduling actions that could dramatically restrict scientific research into promising pain medications, disrupt harm reduction efforts, and push vulnerable individuals toward more dangerous illicit opioids," — Kat Murti, Executive Director, Students for Sensible Drug Policy

Bottom line

With the July 31 public comment deadline approaching, SSDP is urging researchers, clinicians, and patients to submit evidence to docket HHS-OASH-2026-0232 before the DEA's 7-OH scheduling move becomes final.